Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim M Govers

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|January 23, 2019
The potential health gain and cost savings of improving adherence in chronic myeloid leukemiaGeneviève I C G Ector, Tim M Govers, Peter E Westerweel, et al.
BMC Cancer|March 10, 2023
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trialMelissa F Djodikromo, Rosella Pmg Hermens, Bart Jf van den Bemt, et al.
Oral Oncology|June 6, 2013
Management of the N0 neck in early stage oral squamous cell cancer: a modeling study of the cost-effectivenessTim M Govers, Robert P Takes, M Baris Karakullukcu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 28, 2024
The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose ReductionSanne J J P M Metsemakers, Rosella P M G Hermens, Geneviève I C G Ector, et al.
Gynecologic Oncology|February 14, 2021
A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancerLara C Burg, Robin J Vermeulen, Ruud L M Bekkers, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|December 9, 2015
An international comparison of the management of the neck in early oral squamous cell carcinoma in the Netherlands, UK, and USATim M Govers, Tijs B H de Kort, Matthias A W Merkx, et al.
Insights Into Imaging|September 26, 2021
Cost-effectiveness of artificial intelligence aided vessel occlusion detection in acute stroke: an early health technology assessmentKicky G van Leeuwen, Frederick J A Meijer, Steven Schalekamp, et al.
Pharmacoeconomics|February 1, 2023
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAntoinette D I van Asselt, Nigel Armstrong, Merel Kimman, et al.
Journal of Clinical Epidemiology|September 1, 2018
Integrated prediction and decision models are valuable in informing personalized decision makingTim M Govers, Maroeska M Rovers, Marieke T Brands, et al.
BJU International|April 4, 2017
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical modelSiebren Dijkstra, Tim M Govers, Rianne J Hendriks, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|January 23, 2019
The potential health gain and cost savings of improving adherence in chronic myeloid leukemiaGeneviève I C G Ector, Tim M Govers, Peter E Westerweel, et al.
BMC Cancer|March 10, 2023
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trialMelissa F Djodikromo, Rosella Pmg Hermens, Bart Jf van den Bemt, et al.
Oral Oncology|June 6, 2013
Management of the N0 neck in early stage oral squamous cell cancer: a modeling study of the cost-effectivenessTim M Govers, Robert P Takes, M Baris Karakullukcu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 28, 2024
The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose ReductionSanne J J P M Metsemakers, Rosella P M G Hermens, Geneviève I C G Ector, et al.
Gynecologic Oncology|February 14, 2021
A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancerLara C Burg, Robin J Vermeulen, Ruud L M Bekkers, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|December 9, 2015
An international comparison of the management of the neck in early oral squamous cell carcinoma in the Netherlands, UK, and USATim M Govers, Tijs B H de Kort, Matthias A W Merkx, et al.
Insights Into Imaging|September 26, 2021
Cost-effectiveness of artificial intelligence aided vessel occlusion detection in acute stroke: an early health technology assessmentKicky G van Leeuwen, Frederick J A Meijer, Steven Schalekamp, et al.
Pharmacoeconomics|February 1, 2023
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAntoinette D I van Asselt, Nigel Armstrong, Merel Kimman, et al.
Journal of Clinical Epidemiology|September 1, 2018
Integrated prediction and decision models are valuable in informing personalized decision makingTim M Govers, Maroeska M Rovers, Marieke T Brands, et al.
BJU International|April 4, 2017
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical modelSiebren Dijkstra, Tim M Govers, Rianne J Hendriks, et al.
Pageof 3